CYDY - CytoDyn: Preparing For Capitulation After A Successful Failure
- CytoDyn recently reported Leronlimab's CD12 severe-to-critical data. The numbers were lackluster and failed to hit endpoints. Consequently, the bears have remerged and have triggered a substantial sell-off.
- After some analysis, the company revealed a subset of patients who benefited from Leronlimab. Now the company has to build upon that data to prove Leronlimab has a place.
- I believe there is still potential for CytoDyn to keep the COVID-story alive. As a result, I am looking for capitulation while keeping an eye out for a PR.
For further details see:
CytoDyn: Preparing For Capitulation After A Successful Failure